<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005000</url>
  </required_header>
  <id_info>
    <org_study_id>259H</org_study_id>
    <secondary_id>AG1343-1127</secondary_id>
    <nct_id>NCT00005000</nct_id>
  </id_info>
  <brief_title>Treatment With Nelfinavir or Efavirenz of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs</brief_title>
  <official_title>A Randomized, Open-Label, Study of Nelfinavir or Efavirenz in HIV-1 Infected, Antiretroviral Naive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Agouron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare two drugs (nelfinavir [NFV] and efavirenz [EFV]) used
      in start-up anti-HIV treatment. Doctors want to see if one is better than the other in
      extending the time that viral load (level of HIV in the blood) is kept low. The study will
      also look at the response of the immune system to each drug.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients are randomized to initiate therapy and receive either nelfinavir (NFV) or efavirenz
      (EFV) in the first regimen (R1). All patients also receive zidovudine (AZT) and lamivudine
      (3TC). Patients are further randomized in a factorial fashion and by stratification based on
      HIV RNA level (less than 10,000, 10,000-100,000, or greater than 100,000 copies/ml) to be
      administered a single injection of a neo-antigen (KLH) at Week 12, 24, or 48. Therapy
      continues until switch criteria are met either before or after Week 24. When switch criteria
      are met, patients advance to the next regimen (R2).

      R2 patients previously taking NFV switch to EFV; those randomized to EFV switch to NFV; the
      additional NRTIs change to stavudine (d4T) and didanosine (ddI). Therapy is continued for an
      additional 24 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 1999</start_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>200</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nelfinavir mesylate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Keyhole-Limpet Hemocyanin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stavudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Didanosine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Patients may be eligible for this trial if they:

          -  Are HIV-positive.

          -  Have a CD4 count of at least 100 cells/mm3.

          -  Have a viral load of at least 5,000 copies/ml.

        Exclusion Criteria

        Patients may not be eligible for this study if they:

          -  Have taken any antiretroviral (anti-HIV) agent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Agouron Pharmaceuticals Inc</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2002</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2000</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>HIV-1</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Lymphoid Tissue</keyword>
  <keyword>HIV Protease Inhibitors</keyword>
  <keyword>Genotype</keyword>
  <keyword>Phenotype</keyword>
  <keyword>Nelfinavir</keyword>
  <keyword>Reverse Transcriptase Inhibitors</keyword>
  <keyword>Anti-HIV Agents</keyword>
  <keyword>Viral Load</keyword>
  <keyword>Adipose Tissue</keyword>
  <keyword>Glucose</keyword>
  <keyword>Lipids</keyword>
  <keyword>Immunophenotyping</keyword>
  <keyword>efavirenz</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Stavudine</mesh_term>
    <mesh_term>Didanosine</mesh_term>
    <mesh_term>Nelfinavir</mesh_term>
    <mesh_term>Keyhole-limpet hemocyanin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

